New cocktail of cancer drugs aims to shrink tumors in advanced breast cancer
NCT ID NCT06679036
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests several experimental drug combinations (HRS-2189, Fluvastatin, HRS-6209, HRS-8080, HRS-1358) in 300 people with advanced breast cancer that cannot be removed by surgery or has spread. The main goals are to check safety, find the best doses, and see if tumors shrink. Participants must have tried prior hormone therapy, with or without CDK4/6 inhibitors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-2189, Fluvastatin, HRS-6209, HRS-8080, HRS-1358 (drug combinations)
What this could lead to
If successful, this could point toward new combination treatments for advanced breast cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 300 participants, so the main goals are safety and dosing—not proof of effectiveness. Many drug combinations fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin Medical University Affiliated Cancer Hospital
RECRUITINGHarbin, Heilongjiang, 150081, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact